Caprion

Revealing Differences in the Proteome

Biomarker Discovery

Caprion is the leader in proteomic biomarker discovery.

  • Translational research
  • Pharmacodynamics, MOA, drug response
  • Predictive outcome and patient stratification
  • Companion diagnostics
  • Target discovery

Learn more

MRM Assays

Translate your discoveries into clinic with Caprion MRM assays.

  • Multiplexed assays
  • Cost-effective alternative to immunoassays
  • Custom biomarker panels
  • Validation for genomics and biomarker discovery
  • Bioanalytical services for PK studies

Learn more

Immune Monitoring

IMMUNECARTA offers a diverse portfolio of immune monitoring services in a GLP/GCLP compliant environment

  • Phenotypic and functional analyses of innate and adaptive immune responses
  • Up to 14-colour multiparametric flow cytometry
  • Immunological and technical expertise
  • Quality management systems in support of regulatory submissions processes

Learn more

In Vitro Diagnostics

Caprion is helping to deliver the promise of personalized medicine by bridging the innovation gap in diagnostics.

  • Diabetes/Metabolic disease
  • Oncology
  • Infectious disease
  • Additional therapeutic indications

Learn more

Strategic Partners & Alliances

  • National Institute of Allergy and Infectious Diseases

    NIAID funds the Caprion Clinical Protemoics Center for infectious disease research

  • Québec Consortium for Drug Discovery

    The Québec Consortium for Drug Discovery initiated a projects to develop biomarkers for measurment of early stage diabetes disease and therapy response prediction.

    CQDM.org
    Corporate Video

  • Québec Consortium for Drug Discovery

    IMMUNECarta Services specializes in integrated, state-of-the-art immune monitoring services for preclinical and clinical studies under GLP/GCLP conditions and standards.

    IMMUNECarta.com

© 2014 Caprion